Oligonucleotides – Innovation that transforms lives

Emerging as a new treatment option in rare and orphan disease areas, oligonucleotides have matured into a drug class with a broad indication spectrum. The promise of oligonucleotides making a difference to an increasing number of patients.

With decades of experience in the development, production and regulatory support of APIs, Bachem is extending its focus from peptides to oligonucleotides which leads overall to a transformation of the organization. As can be expected from Bachem, this transformation is being executed meticulously, with a strong focus on innovation and quality. Our aim is to be the first-choice oligonucleotide manufacturer.

Resources

Click on Bachems News to see latest News & Events.